{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:31Z","timestamp":1791304231474,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.2119\/molmed.2012.00283","type":"journal-article","created":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T15:13:20Z","timestamp":1362410000000},"page":"1509-1518","source":"Crossref","is-referenced-by-count":93,"title":["High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4"],"prefix":"10.1186","volume":"18","author":[{"given":"Eileen M","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhaan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ishizawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy A","family":"Comhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil C","family":"Erzurum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R","family":"Billiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"18121509_CR1","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","volume":"43","author":"G Simonneau","year":"2004","unstructured":"Simonneau G, et al. (2004) Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43:5S\u201312S.","journal-title":"J. Am. Coll. Cardiol."},{"key":"18121509_CR2","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:13S\u201324S.","journal-title":"J. Am. Coll. Cardiol."},{"key":"18121509_CR3","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1172\/JCI33452","volume":"118","author":"M Rabinovitch","year":"2008","unstructured":"Rabinovitch M. (2008) Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest. 118:2372\u20139.","journal-title":"J. Clin. Invest."},{"key":"18121509_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jacc.2009.04.009","volume":"54","author":"RM Tuder","year":"2009","unstructured":"Tuder RM, et al. (2009) Development and pathology of pulmonary hypertension. J. Am. Coll. Cardiol. 54:S3\u20139.","journal-title":"J. Am. Coll. Cardiol."},{"key":"18121509_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccm.2006.11.010","volume":"28","author":"RM Tuder","year":"2007","unstructured":"Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. (2007) Pathology of pulmonary hypertension. Clin. Chest Med. 28:23\u201342, vii.","journal-title":"Clin. Chest Med."},{"key":"18121509_CR6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/CIRCULATIONAHA.106.673988","volume":"118","author":"ED Michelakis","year":"2008","unstructured":"Michelakis ED, Wilkins MR, Rabinovitch M. (2008) Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation. 118:1486\u201395.","journal-title":"Circulation"},{"key":"18121509_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, et al. (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30:394\u2013403.","journal-title":"Eur. Heart J."},{"key":"18121509_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ahj.2007.02.037","volume":"153","author":"A Macchia","year":"2007","unstructured":"Macchia A, et al. (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 153:1037\u201347.","journal-title":"Am. Heart J."},{"key":"18121509_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1189\/jlb.0306164","volume":"81","author":"ME Bianchi","year":"2007","unstructured":"Bianchi ME. (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81:1\u20135.","journal-title":"J. Leukoc. Biol."},{"key":"18121509_CR10","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1093\/emboj\/cdf692","volume":"21","author":"T Bonaldi","year":"2002","unstructured":"Bonaldi T, Langst G, Strohner R, Becker PB, Bianchi ME. (2002) The DNA chaperone HMGB1 facilitates ACF\/CHRAC-dependent nucleosome sliding. EMBO J. 21:6865\u201373.","journal-title":"EMBO J."},{"key":"18121509_CR11","doi-asserted-by":"publisher","first-page":"C917","DOI":"10.1152\/ajpcell.00401.2005","volume":"290","author":"JS Park","year":"2006","unstructured":"Park JS, et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917\u201324.","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"18121509_CR12","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1074\/jbc.M306793200","volume":"279","author":"JS Park","year":"2004","unstructured":"Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370\u20137.","journal-title":"J. Biol. Chem."},{"key":"18121509_CR13","doi-asserted-by":"publisher","first-page":"25752","DOI":"10.1074\/jbc.270.43.25752","volume":"270","author":"O Hori","year":"1995","unstructured":"Hori O, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752\u201361.","journal-title":"J. Biol. Chem."},{"key":"18121509_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.gastro.2009.09.045","volume":"138","author":"CP Sodhi","year":"2010","unstructured":"Sodhi CP, et al. (2010) Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. Gastroenterology. 138:185\u201396.","journal-title":"Gastroenterology"},{"key":"18121509_CR15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1172\/JCI200418704","volume":"113","author":"B Liliensiek","year":"2004","unstructured":"Liliensiek B, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641\u201350.","journal-title":"J. Clin. Invest."},{"key":"18121509_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1073\/pnas.2434651100","volume":"101","author":"H Yang","year":"2004","unstructured":"Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296\u2013301.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"18121509_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1074\/jbc.M112.434142","volume":"288","author":"EM Bauer","year":"2013","unstructured":"Bauer EM, Shapiro R, Billiar TR, Bauer PM. (2013) High mobility group box 1 inhibits human pulmonary artery endothelial cell migration via a toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J. Biol. Chem. 288:1365\u201373.","journal-title":"J. Biol. Chem."},{"key":"18121509_CR18","doi-asserted-by":"publisher","first-page":"e28578","DOI":"10.1371\/journal.pone.0028578","volume":"6","author":"EM Bauer","year":"2011","unstructured":"Bauer EM, et al. (2011) Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One. 6:e28578.","journal-title":"PLoS One"},{"key":"18121509_CR19","doi-asserted-by":"crossref","unstructured":"Troseid M, et al. (2012) Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: possible implication for TLR4-signalling and chronic immune activation. Innate Immun. 2012, Oct 15 [Epub ahead of print].","DOI":"10.1177\/1753425912461042"},{"key":"18121509_CR20","doi-asserted-by":"crossref","unstructured":"Stoetzer OJ, et al. (2012) Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2012, Sep 15 [Epub ahead of print].","DOI":"10.1007\/s13277-012-0513-1"},{"key":"18121509_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2012.01.040","volume":"221","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, et al. (2012) Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 221:490\u20135.","journal-title":"Atherosclerosis"},{"key":"18121509_CR22","doi-asserted-by":"crossref","unstructured":"Oktayoglu P, et al. (2012) Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol. Int. 2012, Nov 10 [Epub ahead of print].","DOI":"10.1007\/s00296-012-2578-y"},{"key":"18121509_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcv.2012.07.010","volume":"55","author":"D Allonso","year":"2012","unstructured":"Allonso D, et al. (2012) Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. J. Clin. Virol. 55:214\u20139.","journal-title":"J. Clin. Virol."},{"key":"18121509_CR24","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/j.1349-7006.2012.02358.x","volume":"103","author":"HW Chung","year":"2012","unstructured":"Chung HW, et al. (2012) Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci. 103:1714\u201321.","journal-title":"Cancer Sci."},{"key":"18121509_CR25","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/ar3747","volume":"14","author":"A Zickert","year":"2012","unstructured":"Zickert A, et al. (2012) Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res. Ther. 14:R36.","journal-title":"Arthritis Res. Ther."},{"key":"18121509_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3109\/03009742.2011.633099","volume":"41","author":"G Dupire","year":"2012","unstructured":"Dupire G, Nicaise C, Gangji V, Soyfoo MS. (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren\u2019s syndrome. Scand. J. Rheumatol. 41:120\u20133.","journal-title":"Scand. J. Rheumatol."},{"key":"18121509_CR27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/ard.2007.080424","volume":"67","author":"F Iannone","year":"2008","unstructured":"Iannone F, et al. (2008) Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann. Rheum. Dis. 67:1121\u20136.","journal-title":"Ann. Rheum. Dis."},{"key":"18121509_CR28","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732\u20139.","journal-title":"N. Engl. J. Med."},{"key":"18121509_CR29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:1119\u201323.","journal-title":"Lancet"},{"key":"18121509_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","volume":"122","author":"M Humbert","year":"2010","unstructured":"Humbert M, et al. (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 122:156\u201363.","journal-title":"Circulation"},{"key":"18121509_CR31","first-page":"275","volume":"144","author":"RM Tuder","year":"1994","unstructured":"Tuder RM, Groves B, Badesch DB, Voelkel NF. (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144:275\u201385.","journal-title":"Am. J. Pathol."},{"key":"18121509_CR32","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","volume":"54","author":"PM Hassoun","year":"2009","unstructured":"Hassoun PM, et al. (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54:S10\u20139.","journal-title":"J. Am. Coll. Cardiol."},{"key":"18121509_CR33","first-page":"1807","volume":"19","author":"M Dahl","year":"1992","unstructured":"Dahl M, Chalmers A, Wade J, Calverley D, Munt B. (1992) Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J. Rheumatol. 19:1807\u20139.","journal-title":"J. Rheumatol."},{"key":"18121509_CR34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1136\/ard.51.8.1001","volume":"51","author":"DM Friedman","year":"1992","unstructured":"Friedman DM, Mitnick HJ, Danilowicz D. (1992) Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease. Ann. Rheum. Dis. 51:1001\u20134.","journal-title":"Ann. Rheum. Dis."},{"key":"18121509_CR35","doi-asserted-by":"publisher","first-page":"8798","DOI":"10.1073\/pnas.161272598","volume":"98","author":"T Minamino","year":"2001","unstructured":"Minamino T, et al. (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 98:8798\u2013803.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"18121509_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1465-9921-10-6","volume":"10","author":"L Savale","year":"2009","unstructured":"Savale L, et al. (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 10:6.","journal-title":"Respir. Res."},{"key":"18121509_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","volume":"104","author":"MK Steiner","year":"2009","unstructured":"Steiner MK, et al. (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104:236\u201344.","journal-title":"Circ. Res."},{"key":"18121509_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2011","unstructured":"Kumar H, Kawai T, Akira S. (2011) Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30:16\u201334.","journal-title":"Int. Rev. Immunol."},{"key":"18121509_CR39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991\u20131045.","journal-title":"Annu. Rev. Immunol."},{"key":"18121509_CR40","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2119\/2008-00034.Klune","volume":"14","author":"JR Klune","year":"2008","unstructured":"Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. (2008) HMGB1: endogenous danger signaling. Mol. Med. 14:476\u201384.","journal-title":"Mol. Med."},{"key":"18121509_CR41","first-page":"A3413","volume":"183","author":"Y Sadamura","year":"2011","unstructured":"Sadamura Y, et al. (2011) The role of high mobility group box1 in monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 183:A3413.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18121509_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20042614","volume":"201","author":"A Tsung","year":"2005","unstructured":"Tsung A, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135\u201343.","journal-title":"J. Exp. Med."},{"key":"18121509_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nm.2127","volume":"16","author":"M Maroso","year":"2010","unstructured":"Maroso M, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16:413\u20139.","journal-title":"Nat. Med."},{"key":"18121509_CR44","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/emboj.2010.94","volume":"29","author":"D Mittal","year":"2010","unstructured":"Mittal D, et al. (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 29:2242\u201352.","journal-title":"EMBO J."},{"key":"18121509_CR45","doi-asserted-by":"publisher","first-page":"R1538","DOI":"10.1152\/ajpregu.00272.2007","volume":"293","author":"RM Levy","year":"2007","unstructured":"Levy RM, et al. (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R1538\u201344.","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"18121509_CR46","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ki.2011.140","volume":"80","author":"J Chen","year":"2011","unstructured":"Chen J, et al. (2011) Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int. 80:504\u201315.","journal-title":"Kidney Int."},{"key":"18121509_CR47","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1016\/j.molimm.2009.05.179","volume":"46","author":"R Spirig","year":"2009","unstructured":"Spirig R, et al. (2009) TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol. Immunol. 46:3178\u201382.","journal-title":"Mol. Immunol."},{"key":"18121509_CR48","doi-asserted-by":"publisher","first-page":"L2","DOI":"10.1152\/ajplung.00135.2005","volume":"290","author":"JQ Liu","year":"2006","unstructured":"Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. (2006) Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am. J. Physiol. Lung Cell Mol. Physiol. 290:L2\u201310.","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"18121509_CR49","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1073\/pnas.1003893107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942\u20137.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"18121509_CR50","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1182\/blood-2005-03-0916","volume":"106","author":"G Andonegui","year":"2005","unstructured":"Andonegui G, et al. (2005) Platelets express functional Toll-like receptor-4. Blood. 106:2417\u201323.","journal-title":"Blood"},{"key":"18121509_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1006\/bbrc.1997.7263","volume":"238","author":"F Katsuoka","year":"1997","unstructured":"Katsuoka F, et al. (1997) Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem. Biophys. Res. Commun. 238:512\u20136.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"18121509_CR52","doi-asserted-by":"publisher","first-page":"917108","DOI":"10.1155\/2010\/917108","volume":"2010","author":"ST Buckley","year":"2010","unstructured":"Buckley ST, Ehrhardt C. (2010) The receptor for advanced glycation end products (RAGE) and the lung. J. Biomed. Biotechnol. 2010:917108.","journal-title":"J. Biomed. Biotechnol."},{"key":"18121509_CR53","first-page":"1405","volume":"4","author":"MT Lotze","year":"2003","unstructured":"Lotze MT, DeMarco RA. (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs. 4:1405\u20139.","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"18121509_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-0030-1251503","volume":"36","author":"HC Volz","year":"2010","unstructured":"Volz HC, Kaya Z, Katus HA, Andrassy M. (2010) The role of HMGB1\/RAGE in inflammatory cardiomyopathy. Semin. Thromb. Hemost. 36:185\u201394.","journal-title":"Semin. Thromb. Hemost."},{"key":"18121509_CR55","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1517\/14728222.2011.575360","volume":"15","author":"JA Nogueira-Machado","year":"2011","unstructured":"Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. (2011) HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin. Ther. Targets. 15:1023\u201335.","journal-title":"Expert Opin. Ther. Targets."},{"key":"18121509_CR56","doi-asserted-by":"publisher","first-page":"E323","DOI":"10.1152\/ajpendo.00024.2008","volume":"295","author":"C Tikellis","year":"2008","unstructured":"Tikellis C, et al. (2008) Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am. J. Physiol. Endocrinol. Metab. 295:E323\u201330.","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2012.00283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2012.00283\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2012.00283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2012.00283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T07:34:22Z","timestamp":1562744062000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2012.00283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["18121509"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2012.00283","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}